WASHINGTON - While the more than $6 billion increase in President Obama's fiscal year 2010 budget proposal for cancer research is a positive step in finding new cures, that progress could be for naught if Congress fails to give biotech companies - which are involved in developing and advancing more than 250 investigational cancer products - tax breaks and other needed help to survive the economic downturn, said Jim Greenwood, CEO of the Biotechnology Industry Organization (BIO). (BioWorld Today)
